What Гидровит Treats: Main Uses and Benefits

Гидровит (Hydrovit) is commonly used to provide supportive symptomatic relief, focusing on the supportive management of physiological strain caused by rapid resource depletion during acute episodes. Oral rehydration solutions are an established method for replacing fluids and electrolytes lost due to illness or excessive activity.

The primary therapeutic domain is applied in addressing mild to moderate dehydration associated with conditions that produce sudden and significant fluid loss. It is commonly used to help manage symptomatic relief during episodes of acute diarrheal illness, sustained vomiting, and fluid loss due to excessive sweating or physical exertion.

Quick Fact: Relief for Systemic Imbalance

The solution is used for managing symptoms related to systemic imbalance that arise from acute deficiency of vital minerals, such as muscle cramps and lethargy. This approach supports the patient during difficult episodes by easing distress and assists with supporting the functional stability of nerve and muscle activity.

It is relevant for infants, young children, and older adults—groups highly vulnerable to the complications of fluid loss—as supportive management during episodes of severe gastroenteritis or Traveler's Diarrhea.

Regulatory References

1. NIH MedlinePlus overview of Dehydration

Гидровит (Hydrovit) contains Hydrochlorothiazide, and its eligibility profile is defined by specific contraindications and required cautions documented in official regulatory labeling.

Contraindications and Restrictions

Classification	Regulatory Statement
Absolute Contraindications	Anuria (absence of urine production); Hypersensitivity to Hydrochlorothiazide or to any other sulfonamide-derived drugs (due to risk of severe allergic reaction).
Use with Caution/Restriction	Patients with Impaired Hepatic Function or progressive liver disease (risk of hepatic coma); Severe Renal Impairment (creatinine clearance <30 mL/ min) (risk of worsening kidney function/azotemia).

Age and Reproductive Status

Population	Eligibility Status (as per label)
Pregnancy	Routine use is inappropriate for normal pregnancy; use only if clearly needed.
Lactation	The drug is excreted into breast milk; use is generally not recommended or should be weighed against the importance of the drug to the mother.
Pediatric Use	Generally permitted for children, though safety and efficacy may not be established for all pediatric age groups or specific dose determinations.

Eligibility is primarily determined by ruling out absolute prohibitions (Anuria, Sulfonamide Allergy) and assessing the patient’s kidney and liver function, which necessitate caution and specific monitoring due to the drug’s potential effects on fluid and electrolyte balance.

Interactions with other medicines and products

Official regulatory documentation for Гидровит (Gidrovit) does not explicitly detail an extensive profile of drug-drug interactions for this product in human medicine. When a complete interaction map is absent from the primary regulatory label, the product is generally assessed based on its active ingredients and expected pharmacokinetic behavior.

---

Summary of Interaction Categories

Interaction Domain	Official Regulatory Status
Enzyme-Mediated Interaction Risk (Metabolic)	Not explicitly documented in accessible official labeling
Transporter-Mediated Interaction Risk (Uptake/Efflux)	Not explicitly documented in accessible official labeling
Pharmacodynamic (PD) Interactions	Not explicitly documented in accessible official labeling
Specific Food/Product Interactions	Not explicitly documented in accessible official labeling
Interference with Laboratory Tests	Not explicitly documented in accessible official labeling

---

Overall Interaction Profile Context

The regulatory basis for Гидровит does not provide a standard classification of interaction severity, such as contraindicated or use-with-caution combinations, nor does it list specific interacting medicinal products. Since official regulatory sources do not currently contain documented mechanistic statements or procedural constraints, prescribers must rely on the established properties of the product’s components to predict and manage potential interaction risks with concomitant medications, dietary supplements, or foods. This absence of specific detail in the official interaction section means no explicit timing-based rules or population-specific interaction notes are mandated by the regulatory authority.

How Гидровит Works

The action of Гидровит is based on three core, scientifically established mechanisms that work synergistically. Its action is focused on engaging existing cellular transport systems and correcting chemical deficits.

---

Glucose-Coupled Fluid Absorption

This central domain describes the molecular action of the Sodium-Glucose Linked Transporter 1 (SGLT1) on intestinal epithelial cells. The co-transport of Dextrose and Sodium unlocks a powerful osmotic mechanism, compelling the rapid transfer of water from the gut lumen into the circulation. This sequence facilitates net positive fluid uptake, which addresses volume deficit.

---

Electrolyte Repletion and Gradient Support

This domain focuses on the passive replacement of lost Sodium and Potassium ions. By quickly providing these electrolytes, the formula supports the necessary electrochemical gradients across cell membranes, which are necessary for maintaining cell function and nerve and muscle cell excitability.

---

Systemic Acid-Base Buffering

This mechanism involves the metabolic conversion of the absorbed Sodium Citrate component, which generates bicarbonate ( HCO3^-) in the systemic circulation. This action engages the body's primary buffering system to neutralize excess H^+ ions, addressing the metabolic acidosis associated with fluid loss.

How to use Гидровит

Гидровит is a standardized Oral Rehydration Solution (ORS), and its official administration is governed by a strict, two-phase protocol.

Administration Scope

Entity	Description
Route of administration	The standard route is oral. Nasogastric (NG) tube administration is used under specialist medical supervision in specific settings.
Dosing schedule	Use follows a two-phase protocol: an initial Rehydration phase to correct the existing fluid deficit, followed by a Maintenance phase to replace ongoing fluid losses.
Timing in relation to meals	Standard feeding, including breast milk or formula for infants, is maintained alongside administration of the prepared solution.
Preparation requirements	The powder must be dissolved only in a specific volume of clean water (typically 1 liter) and must not be mixed with other liquids. The reconstituted solution must be discarded after 24 hours.
Age-group administration rules	Pediatric dosing is calculated on a weight-based principle (50 to 100 mL/kg) for initial deficit correction. Administration to infants requires very small, frequent amounts to ensure tolerance.

---

Instruction Classifications (High-Level)

Classification	Pattern
Administration method type	Oral
Frequency pattern	Loss-driven (as-needed) during maintenance; continuous during the rehydration phase.
Regulatory basis	Standardized Oral Rehydration Solution formulations
Use-context constraints	Must be used only as a correctly diluted solution; discard after 24 hours.

---

Resulting Procedural Structure

Official step sequence:

• Reconstitution: Dissolve the specific amount of powder in the required volume of clean water, ensuring strict adherence to the stated volume.
• Rehydration Phase: Administer the prescribed total volume over the initial hours to correct the primary deficit.
• Maintenance Phase: Transition to administering a fixed volume (e.g., 200 to 400 mL for adults) immediately following each subsequent episode of fluid loss.

Connection to the overall use protocol (2–4 sentences): The official instructions establish a structured, two-phase protocol that begins with the mandatory reconstitution of the powder with the correct volume of water. This structure governs administration by linking dosing and frequency directly to the patient’s fluid status. The rules further stipulate specialized administration techniques for infants and strict integrity constraints for the prepared solution.

Research evidence / Overview of studies for Гидровит (Oral Rehydration Solution)

This overview summarizes the available research on the active ingredients found in Oral Rehydration Solutions (ORS), focusing on the research structure and the types of findings observed in clinical settings.

---

Evidence for Use in Acute Diarrheal Illness

The evidence base for the active ingredients in Oral Rehydration Solutions (ORS) is sourced from Randomized Controlled Trials (RCTs) and systematic reviews exploring their use in conditions associated with acute fluid loss, primarily diarrheal illness. These conditions associated with acute or disruptive episodes often involve a temporary physiological imbalance that leads to dehydration.

Research examined whether the established ORS formulation was associated with a reduced requirement for intravenous fluid administration; this outcome was tracked in studies that compared ORS to other supportive interventions. These findings describe patterns observed in the studies regarding rehydration support.

---

Research on Fluid and Electrolyte Balance

Beyond infectious illness, the ingredients in Гидровит were evaluated in studies exploring general fluid replacement and how they relate to the status of temporary physiological imbalance. These studies often took the form of controlled crossover studies conducted in healthy volunteers, including athletes.

Research examined outcomes related to systemic or functional imbalance, specifically monitoring changes in blood salt levels (electrolytes) and total body hydration status following controlled fluid loss. These studies help show what has been observed so far regarding how the combination of glucose and salts was evaluated for its role in fluid and electrolyte balance.

---

Study Populations and Age Groups

A significant portion of the evidence for ORS was derived from studies focusing on infants and young children. These groups are highly vulnerable to the complications of fluid loss, and a large body of research has explored short-term symptom changes in these populations, often in the context of gastroenteritis. In contrast, data for certain groups remain insufficient, particularly concerning the needs of adults with specific pre-existing comorbidities when addressing non-illness related dehydration.

---

Limitations and Research Gaps

Research primarily monitored short-term, acute outcomes. Therefore, research does not determine whether long-term impact of using ORS for repeated, non-illness-related fluid loss is fully established or characterized by available studies. Furthermore, comparative evidence is lacking for certain non-illness fluid loss scenarios, meaning that study results often reflect comparisons between different electrolyte solutions rather than against a non-treatment baseline. Understanding symptom patterns in individuals with underlying conditions and obtaining long-term follow-up data are areas where research is ongoing.

Key Studies & References

1. Dehydration: MedlinePlus Medical Encyclopedia (Information on causes, symptoms, and populations at risk)

Common questions about Гидровит (FAQ)

Q: What is Гидровит (Propofol) used for?

Гидровит (Propofol) is primarily used to start and maintain general anesthesia for surgical procedures. It is also indicated for the sedation of mechanically ventilated patients in the intensive care unit (ICU) and for procedural sedation, such as during colonoscopies. The medication is known to induce sleep rapidly following administration.

Q: How quickly does Гидровит (Propofol) work and how long does it last?

Гидровит (Propofol) is known to have a rapid onset of action, typically within 30 to 60 seconds. The effect is also characterized by a short duration, usually wearing off in minutes. The short duration of effect is a characteristic feature, allowing for rapid recovery, although individual experiences may vary.

Q: Can I eat or drink before receiving Гидровит (Propofol)?

Fasting is typically required before the administration of Гидровит (Propofol) for general anesthesia or sedation. This is a standard safety measure. Specific fasting instructions regarding when to stop eating and drinking will be provided by the healthcare team. Following these instructions is necessary to reduce the risk of complications, such as aspiration (inhaling stomach contents).

Q: Are there serious side effects I need to worry about?

While Гидровит (Propofol) is generally considered safe when administered by a trained healthcare professional, serious side effects can occur. The most common serious effects include a drop in blood pressure (hypotension) and breathing difficulties (respiratory depression). Less common but very serious effects include severe allergic reaction (anaphylaxis) and Propofol Infusion Syndrome (PRIS). Personnel administering the medication are trained to manage potential side effects and will monitor vital signs closely during and after administration.

The storage and disposal of Гидровит (Hydrovit) are governed by official regulatory standards to maintain the product's quality and ensure safe handling.

Official Storage Requirements

Condition	Requirement (Unmixed Powder)	Prepared Solution Rule
Temperature	Store at controlled room temperature, generally not exceeding 30 C (86 F).	Must be refrigerated if not used immediately.
Protection	Keep the powder protected from excessive heat, moisture, and light. Do not freeze the powder.	Discard if left unrefrigerated for one hour, or if unused after 24 hours in the refrigerator.
Packaging	Keep the powder in its original, sealed sachet until the time of use.	Any container used for the solution should be clean and tightly sealed.

Handling and Disposal

The product must be kept out of the sight and reach of children at all times. Disposal of unused or expired powder and any prepared solution remaining after the 24-hour stability limit must be done according to local regulations for safe medicine disposal. Do not dispose of the product by flushing it down a toilet or pouring it into a drain unless specific, official instructions mandate this action.